INTRODUCTION — Acute rhinosinusitis (ARS) is defined as symptomatic inflammation of the nasal cavity and paranasal sinuses lasting less than four weeks. The term "rhinosinusitis" is preferred to "sinusitis" since inflammation of the sinuses rarely occurs without concurrent inflammation of the nasal mucosa [1].
Classification of rhinosinusitis is based on symptom duration.
- Acute rhinosinusitis - symptoms for less than four weeks
- Subacute rhinosinusitis - symptoms for four to twelve weeks
- Chronic rhinosinusitis - persists greater than twelve weeks (graph 1).
- Recurrent acute rhinosinusitis - four or more episodes of ARS per year, with interim symptom resolution [2].
Acute rhinosinusitis is further specified as acute bacterial rhinosinusitis (ABRS) or acute viral rhinosinusitis (AVRS).
The most common etiology of ARS is a viral infection associated with the common cold. Viral rhinosinusitis is complicated by acute bacterial infection in only 0.5 to 2 percent of episodes. Uncomplicated AVRS typically resolves in 7 to 10 days. ABRS also is most commonly a self-limited disease, with 75 percent of cases resolving without treatment in one month. Rarely, patients with untreated bacterial disease may develop serious complications. (See "Preseptal (periorbital) and orbital cellulitis".)
Distinguishing AVRS of colds and influenza-like illnesses from bacterial infection is a frequent challenge to the primary care clinician. Antibiotics may be indicated for ABRS, but are ineffective and not recommended for AVRS. Despite the overwhelming prevalence of a viral etiology, however, 92 percent of patients in the United Kingdom [3] and 85 to 98 percent of patients in the United States (US) [4] are prescribed an antibiotic when seen for an upper respiratory or sinus infection.
This topic will address the diagnosis and treatment of acute rhinosinusitis. Chronic rhinosinusitis is discussed separately. (See "Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis" and "Management of chronic rhinosinusitis".) Diagnosis and management of the common cold is also discussed separately. (See "The common cold in adults: Diagnosis and clinical features" and "The common cold in adults: Treatment and prevention".)
EPIDEMIOLOGY — Sinusiits affects more than 30 million adults in the United States annually [2].
Direct costs of sinusitis in the US, resulting from medications, outpatient and emergency room visits, ancillary tests and procedures, are estimated at $3 billion per year [2,5]. The socioeconomic impact is further magnified by indirect costs from decreased productivity, days lost from work, and impaired quality of life.
PATHOPHYSIOLOGY — The vast majority of cases of acute rhinosinusitis (ARS) are due to viral infection. As noted above, acute bacterial infection occurs in only 0.5 to 2 percent of episodes. The most common viruses, determined by maxillary sinus puncture and aspiration, are rhinovirus, influenza virus, and parainfluenza virus [6].
AVRS begins with viral substrate inoculation via direct contact with conjunctiva or nasal mucosa. Viral replication in a nonimmune individual leads to detectable viral levels in nasal secretions within 8 to 10 hours. Symptoms, if they develop, usually present within 8 to 12 hours of inoculation.
Viral rhinitis spreads to the paranasal sinuses by systemic or direct routes. Nose blowing may be an important mechanism; positive intranasal pressures generated during nose blowing may propel contaminated fluid from the nasal cavity into the paranasal sinuses [7]. Inflammation follows, resulting in sinonasal hypersecretion and increased vascular permeability, followed by transudation of fluid into the nasal cavity and sinuses. Viruses also can exert a direct toxic effect on nasal cilia, impairing mucociliary clearance. A combination of mucosal edema, copious thickened secretions, and ciliary dyskinesia results in sinus obstruction and perpetuates the disease process [8].
Community-acquired acute bacterial rhinosinusitis (ABRS) occurs when bacteria secondarily infect the inflamed sinus cavity. Though usually occurring as a complication of viral infection, other predisposing conditions associated with acute bacterial sinusitis include allergy, mechanical obstruction of the nose, swimming, odontogenic infection, intranasal cocaine use, impaired mucociliary clearance (eg, cystic fibrosis, cilial dysfunction), immunodeficiency, and other factors that impair sinus drainage [9].
Normal respiratory flora in adults typically includes coagulase-negative Staphylococci, Corynebacterium and Staphylococcus aureus. The most common bacteria associated with ABRS are Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis, with the first two comprising approximately 75 percent of cases (table 1). When ABRS is due to extension of dental root infection into the sinus cavity, microaerophilic and anaerobic bacteria may be identified.
Community-acquired ABRS is typically caused by a single pathogen in high concentration (>100 colony-forming units [CFU]), although two distinct pathogens in high concentrations are isolated in approximately 25 percent of patients [10].
CLINICAL MANIFESTATIONS — Symptoms of acute rhinosinusitis include nasal congestion and obstruction, purulent nasal discharge, maxillary tooth discomfort, and facial pain or pressure that is worse when bending forward [11,12]. Other signs and symptoms include fever, fatigue, cough, hyposmia or anosmia, ear pressure or fullness, headache, and halitosis.
Indications for urgent referral — Patients with high fever, acute facial pain, swelling, and erythema should be treated for acute bacterial rhinosinusitis, even if symptoms have not been present for seven days. Patients with high fevers and severe headache warrant immediate evaluation and probable imaging.
The finding of any of the following should lead to urgent referral to a specialist for the possibility of complications of sinusitis, including intracranial and orbital extension [13]:
- Abnormal vision (diplopia, blindness)
- Change in mental status
- Periorbital edema
DIAGNOSIS — Analysis of the predictive value of multiple signs and symptoms has identified the following as most highly predictive of acute sinusitis, whether viral or bacterial [2]:
- Purulent rhinorrhea
- Nasal congestion and/or facial pain/pressure.
The diagnosis is further supported by the presence of secondary symptoms, including anosmia, ear fullness, cough, and headache.
Clinical presentation is unfortunately of limited accuracy in distinguishing pure viral rhinosinusitis from secondary bacterial infection [14]. Several clinical criteria have been suggested to distinguish bacterial and viral infection, based on studies with methodological flaws including lack of gold standards for establishing diagnosis and response, and heterogeneous patient selection criteria [4,11,15,16]. Berg and Carenfelt criteria for bacterial sinus infection are based on symptom correlation with bacterial cultures from antral puncture [17]; these criteria, however, may not be applicable to a primary care population.
Symptom duration and progression — The diagnosis of viral rhinosinusitis is based primarily upon history of the quality, duration, and progression of symptoms. Partial or complete resolution of symptoms within seven to ten days following the onset of an upper respiratory tract infection is indicative of AVRS [2,17-21]. In comparison, the probability of identifying a bacterial infection by sinus aspiration is about 60 percent for patients with symptoms persisting beyond ten days [22].
A panel organized by the Centers for Disease Control, including representatives of the American Academy of Family Physicians, American College of Physicians, American Society of Internal Medicine, and the Infectious Diseases Society of America, identified the following symptoms as suggestive of ABRS [4,23,24]:
Rhinosinusitis symptoms lasting seven or more days and any of the following:
- Purulent nasal discharge, or
- Maxillary tooth or facial pain, especially unilateral, or
- Unilateral maxillary sinus tenderness, or
- Worsening symptoms after initial improvement
Worsening of rhinosinusitis symptoms after an initial improvement (double worsening) is particularly suggestive of ABRS [2,21].
Physical examination — Physical examination should encompass the usual evaluation for respiratory infections, including assessment of vital signs, eyes, ears, pharynx, teeth or sinus tenderness, lymph nodes, and chest. While direct visualization of the sinuses is not possible, a handheld otoscope or nasal speculum can be used to perform anterior rhinoscopy.
Notable exam findings may include diffuse mucosal edema, narrowing of the middle meatus, inferior turbinate hypertrophy, and copious rhinorrhea or purulent discharge. Polyps or septal deviation may be noted incidentally and may indicate pre-existing anatomic risk factors for the development of ABRS.
Transillumination of the sinuses has limited value as a diagnostic technique [25]. It is of potential use only for examining the maxillary and frontal sinuses, and does not distinguish viral from bacterial acute rhinosinusitis.
Microbiologic culture — Viral culture of nasal secretions is impractical and unnecessary, given the self-limited nature of AVRS.
Bacterial culture of material from blind swabs of the nasal cavity or from purulent nasal secretions is not recommended, as results are not reliable. Therefore, patients who require antibiotic therapy will generally be treated empirically in the primary care setting, with antibiotic choice based on likely pathogen and susceptibility. (See 'Treatment' below.)
Endoscopic cultures can be performed with minimal morbidity in the otolaryngologist's office (figure 1) and are better tolerated than classic antral puncture with a large bore trocar or needle passed through the canine fossa or inferior meatus [26-28]. Endoscopically-guided middle meatal cultures correlated with cultures performed during maxillary antrostomy in 86 percent of patients in one study [29] and with maxillary punctures in 90 percent in a small prospective series [30].
Endoscopic or sinus aspirate culture, while not indicated in routine medical practice, should be considered if there is a suspicion of intracranial extension of the infection or other serious complications. Culture may also be helpful in patients where atypical pathogens may be suspected, including patients with nosocomial sinusitis, immunocompromise, cystic fibrosis, or recent hospitalization. Cultures are also indicated in patients with documented sinusitis who are not responding to empiric antibiotic therapy.
Radiologic tests — Radiography is generally not indicated in the initial evaluation of ARS. Plain sinus films and sinus CT may show sinus fluid levels in patients with both AVRS and ABRS and cannot distinguish between viral and bacterial etiologies. Common findings of sinusitis on CT include air-fluid levels, mucosal edema, and air bubbles within the sinuses (figure 2).
Some form of mucosal abnormality on CT scan may be observed in as many as 42 percent of asymptomatic healthy individuals [31,32]. In one study of 31 patients with self-diagnosed "colds" confirmed by viral culture, mucosal thickening or air-fluid levels of the maxillary sinuses were found on CT scan within 2 to 3 days of symptom onset in 87 percent [33]. CT abnormalities were also documented in ethmoid, frontal and sphenoid sinuses (65, 32, and 39 percent, respectively). Resolution of radiographic abnormalities occurred by two weeks and no subject received antibiotic therapy.
While not helpful in differentiating between viral and bacterial etiology, CT imaging is useful in refuting sinusitis as a diagnosis. Diagnoses such as allergy or non-allergic rhinitis, or atypical facial pain, might be considered in the absence of radiologic evidence of sinonasal mucosal edema or an air-fluid level. It is reasonable to consider CT imaging in patients with persistent symptoms in whom rhinosinusitis is not clearly suspected and one hopes to avoid a trial of empiric antibiotics.
Imaging studies are indicated in patients with clinical signs or symptoms of complicated ABRS including diminished visual acuity, diplopia, periorbital edema, severe headache, or altered mental status. Imaging may also be helpful in recurrent or treatment-resistant sinusitis to help delineate anatomic blockage of the osteomeatal complex [34].
Noncontrast CT scan is generally acknowledged to be the imaging procedure of choice for the sinus. CT is preferable to plain films for its ability to discern bony and soft tissue detail. Additionally, the sensitivity and specificity of plain sinus radiography is poor for detecting mucosal thickening of the paranasal sinuses (76 and 79 percent, respectively) [35,36]. The high false negative rate is attributable to poor visualization of the ethmoid sinuses in plain films, and the high false positive rate to artifact and the inability to distinguish polyps and nasal masses from fluid or mucosal edema.
MRI is not indicated for routine evaluation of ABRS. It provides complementary soft tissue detail and is used in conjunction with CT for the evaluation of complications of acute rhinosinusitis, when extra sinus involvement is suspected.
Ultrasonography is of limited use in the diagnosis of ABRS, due to its high operator variability and inferior accuracy relative to other modalities [37,38].
TREATMENT — Treatment of viral rhinosinusitis aims to relieve symptoms of nasal obstruction and rhinorrhea; treatment does not shorten the clinical course of the disease. Treatment of ABRS may include antibiotics to eliminate the infection and prevent complications, although 40 to 60 percent of patients with ABRS will clear their infection spontaneously [39].
It is generally not possible to distinguish AVRS from ABRS in the first ten days of illness, based on history, examination, or radiologic study. Since AVRS is expected to resolve within ten days, and ABRS may also resolve spontaneously within the first ten days, patients who present with fewer than ten days of symptoms in general should be managed with supportive care [40]. Exceptions would be patients who experience clinical worsening after initial improvement ("double sickening"), patients with severe symptoms and clearly worsening clinical course, and immunocompromised patients.
Acute viral rhinosinusitis — AVRS is a self-limited process. Treatment is supportive, aimed at symptom relief.
- Analgesics such as nonsteroidal anti-inflammatories and acetaminophen are recommended for pain relief.
- Mechanical irrigation with buffered, hypertonic saline may reduce the need for pain medication and improve overall patient comfort, particularly in patients with frequent sinus infections (table 2) [2,41].
- Topical glucocorticoids (corticosteroids) have been shown to be beneficial as monotherapy for VRS [42]. A randomized trial of mometasone furoate 200 mg twice daily was superior to placebo and to amoxicillin in 981 subjects without ABRS, with symptom relief reported following two to three days of use.
- Topical decongestants, such as oxymetazoline, have been shown to significantly reduce edema, but should be used sparingly (no more than three consecutive days) to avoid rebound congestion [43]. When compared to systemic decongestants, topical therapy appears to be as effective, if not more effective, and has the advantage of fewer side effects [2,44].
- Rhinorrhea associated with the common cold and allergic rhinitis results from parasympathetic stimulation of the submucous gland of the paranasal mucosa. Topical ipratropium bromide 0.06 percent has been shown to significantly diminish such rhinorrhea [45].
- Antihistamines are frequently prescribed for symptom relief due to their drying affects, however there are no studies investigating their efficacy for this indication [2]. Additionally, over-drying of the mucosa may lead to further discomfort. Use in nonatopic patients should thus be limited to avoid potential side effects at the expense of little potential therapeutic benefit.
- Mucolytics such as guaifenesin serve to thin secretions and may promote ease of mucus drainage and clearance. However, no published trials exist to definitively support their use [2].
- Zinc preparations including lozenges, nasal sprays and nasal gels have been used to hasten recovery in the common cold, though a structured review concluded that three of four well-designed studies showed no benefit for zinc lozenges or nasal spray; the fourth reported a positive benefit from a zinc-containing nasal gel [46,47]. Caution must be exercised in the use of such preparations as they have been implicated in hyposmia and anosmia. (See "The common cold in adults: Treatment and prevention", section on 'Zinc'.)
Community-acquired acute bacterial rhinosinusitis — For patients who present with 10 or more days of symptoms (purulent rhinorrhea, nasal congestion and facial pressure), the likelihood of a diagnosis of ABRS increases. There are two acceptable treatment options for patients with mild symptoms for ten or more days: observation, or empiric antibiotic therapy.
Observation — Observation is considered a viable option due to a high rate of spontaneous resolution in community-acquired, uncomplicated rhinosinusitis, as evidenced by randomized, controlled studies of antimicrobials versus placebo [48,49].
Watchful waiting, with assurance of follow-up, has been recommended in 2007 guidelines from a multidisciplinary expert panel for selected patients with symptoms suggestive of mild ABRS [2]:
- Mild pain
- Temperature <38.3 C or 101 F
Patients under observation should be treated supportively for relief of symptoms for seven days after the time of diagnosis. If there is no improvement over this interval, or if there is worsening at any time, antimicrobial therapy is then initiated.
Factors such as age, general state of health, and comorbidities should be considered when choosing this option. Patients with moderately severe symptoms who meet clinical criteria for ABRS, and patients with severe symptoms regardless of duration of illness, should be treated with an antibiotic. (See 'Antimicrobials' below.)
Antimicrobials — Several studies and meta-analyses have addressed the efficacy of systemic antibiotics in the treatment of ARS. Given the difficulty in distinguishing viral from bacterial infection, these studies are complicated by heterogeneity in patient symptoms, underlying etiology, and outcomes of treatment.
- A 2008 meta-analysis based on individual patient data (n = 2547) from 9 randomized trials found that 15 patients with rhinosinusitis would need to be treated with antibiotics before one additional patient would be cured [14]. Clinical signs and symptoms did not define a patient subgroup that was more likely to benefit from treatment, or distinguish viral from bacterial infection.
- Another 2008 meta-analysis pooled results from 17 randomized trials in which acute sinusitis was variably diagnosed (the majority by clinical criteria, but also imaging, microbiology, and inflammatory markers) [50]. There was variability in choice of antibiotic, use of ancillary therapy, and inclusion of children (3 studies). Compared to placebo, antibiotics were associated with a higher rate of cure or symptom improvement at 7 to 15 days (OR 1.64, 95% CI 1.35-2.0), but the magnitude of effect was moderate (cure or improvement in 77 percent with antibiotics versus 68 percent with placebo). The 9 percent difference in cure/improvement rate with antibiotic therapy was at the expense of an 8 percent increase in adverse effects, mostly gastrointestinal (30 percent versus 22 percent for placebo-treated patients).
- A meta-analysis that analyzed data from five trials comparing antibiotics to placebo, defining failure as lack of cure or improvement at 7 to 15 days follow-up, found an increased response rate for antibiotics (RR 0.66, 95% CI 0.44-0.98) [51]. 80 percent of the participants not treated with antibiotics, and 90 percent of the antibiotic group, improved within two weeks. No one antibiotic was superior to another in the review of 51 studies comparing antibiotics.
When antibiotics are administered, treatment is most often initiated empirically. An antimicrobial with the narrowest spectrum against the most probable pathogen(s) is advised to minimize the risk of promoting drug resistance. Although culture-guided therapy is optimal, obtaining suitable cultures requires endoscopy or antral puncture and is generally reserved for patients with complications. (See 'Microbiologic culture' above.)
Four meta-analyses have concluded that newer and broad spectrum antibiotics are not significantly more effective than narrow spectrum antibiotics in patients with acute bacterial sinusitis [51-54]. A retrospective cohort study of 29,102 adults found nearly identical results with amoxicillin, trimethoprim-sulfamethoxazole, or erythromycin compared with broader spectrum antibiotics [55]. We prefer a 10 to 14 day course of amoxicillin (500 mg three times a day) for its narrow spectrum, relatively low cost, and low side-effect profile.
Trimethoprim-sulfamethoxazole and macrolides are cost-effective acceptable alternative first-line therapies in penicillin allergic patients [2]. Macrolides possess anti-inflammatory properties that may add additional therapeutic benefit. Locoregional histograms of bacterial resistance should be referenced to understand resistance trends in the local community.
Increasing rates of penicillin resistance due to beta-lactamase producing S. pneumoniae have led to higher dosing regimens of amoxicillin, or a change in class of antimicrobial. Resistance rates vary regionally and range from 15 to 25 percent for intermediate or highly resistant streptococci in the US [5,56]. High-dose amoxicillin (1 gram four times daily) can be used to treat intermediate-resistant S. pneumoniae. However, beta-lactamase producing M. catarrhalis and H. influenzae cannot be overcome by higher dosing [2] and may require combination therapy with clavulanate. Cefpodoxime, cefdinir, and cefuroxime are also acceptable choices for alternative coverage [57].
Topical glucocorticoids — Topical glucocorticoid (corticosteroid) therapy reduces inflammation and edema in the nasal mucosa, and may be beneficial in the setting of acute inflammation and bacterial infection.
Published reports investigating topical glucocorticoids should be interpreted with caution, as they often contain both heterogeneous patient populations (acute, chronic and/or viral rhinosinusitis) and treatment regimens (concomitant decongestant, saline irrigation, antibiotic). A meta-analysis of three studies, involving patients with ABRS diagnosed by symptoms and confirmed by radiological or endoscopic studies, found that use of intranasal steroids, alone or as adjuvant therapy to antibiotics, increased the rate of symptom response compared to placebo (RR 1.11, 95 % CI 1.04-1.18) [58]. One randomized study of patients with ABRS did not demonstrate benefit for intranasal glucocorticoids [59]. Subgroup analysis of this study, however, found that patients with less severe symptoms did benefit, possibly because thicker nasal secretions and closed ostia in patients with more severe illness limit penetrance of the topical steroids [59].
Systemic glucocorticoids — Unlike topical glucocorticoids, systemic glucocorticoids possess a significant side effect profile, including hyperglycemia, hypertension, increased appetite, mood changes, and insomnia, as well as effects on bone metabolism and cataract formation with more chronic exposure. There are no controlled clinical trials of systemic glucocorticoids available in the treatment of ARS and we suggest not using them in the outpatient treatment of acute rhinosinusitis.
Adjunctive therapy — Symptomatic relief measures, including analgesics, nasal saline irrigation, and topical and systemic decongestants, are appropriate for patients with ABRS and are discussed in the section on acute viral rhinosinusitis. (See 'Acute viral rhinosinusitis' above.)
Treatment failure — Treatment failure is defined as progression of symptoms at any time during treatment or failure to improve after seven days of therapy. Patients who fail first-line therapy require alternative antibiotic selection. Ideally, an endoscopically-guided culture could be performed to redirect antibiotic therapy. If no material is available on endoscopy for culture, a broader antibiotic choice can be empirically started and monitored for improvement. Levofloxacin or high-dose amoxicillin-clavulanate (4 grams/250 milligrams per day) have been recommended [5].
A CT scan of the sinuses may be performed if symptoms worsen or fail to improve, to verify that symptoms are in fact due to acute sinusitis, and not to concomitant allergy or other noninfectious etiologies.
Relapse after treatment — Recurrence of symptoms within two weeks of response to initial treatment usually represents inadequate eradication of infection. Patients who had a good response to initial therapy and who have mild symptoms of relapse can be treated with a longer course of the same antibiotic.
Patients who had only minimal symptom response with the initial antibiotic or whose relapse is moderate to severe, however, are more likely to have organisms resistant to the initial empiric antibiotic and would require a change in the drug selected (see 'Treatment failure' above.
Surgery — There is no indication for surgery in patients with uncomplicated ABRS. However, surgery may be emergently indicated in patients experiencing extra-sinus complications of ABRS including periorbital and orbital abscess, epidural abscess, meningitis, and brain abscess.
Nosocomial bacterial rhinosinusitis — Patients with extended stays in the intensive care unit (ICU), burn victims and those with prolonged intubation, particularly nasotracheal, are at increased risk of developing ABRS [60]. Acute sinusitis affects 1 to 8 percent of patients in the ICU, and usually presents as fever of unknown origin.
Gram-negative organisms including Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, Proteus mirabilis, Serratia marcescens and some gram-positive cocci, in particular S. Aureus, predominate in nosocomial infections [1,61].
Most patients will respond to conservative therapy with removal of nasal foreign bodies, and treatment with nasal decongestants and culture-directed antibiotic therapy. If these measures fail, surgery may be indicated [61].
Acute invasive fungal rhinosinusitis — Acute, fulminant invasive fungal rhinosinusitis (IFRS) is a disease of immunosuppressed patients or patients with poorly controlled diabetes. The rapidly progressive and life-threatening nature of such an infection makes early diagnosis of paramount importance. If a diagnosis of IFRS is entertained, immediate consultation of an otolaryngologist is mandated.
Diagnosis is made by endoscopic examination and biopsy. Rhinoscopy may show either pale, ischemic mucosa or dusky, purplish mucosa with crusting. Histopathology demonstrates intravascular tissue invasion by fungal organisms. The most common species are Mucor, Rhizopus, Aspergillus, Absidia and Basidiobolus [62]. Radiographic studies are ancillary, and should not be relied on for treatment decision making.
Treatment is primarily emergency surgical debridement and, if possible, correction of the underlying immunologic derangement. Secondary treatment includes systemic anti-fungal therapy. Despite timely surgical debridement, and appropriate adjuvant medical treatment, mortality rates remain upwards of 50 percent. (See "Fungal sinusitis".)
COMPLICATIONS
Complications of AVRS, aside from ABRS, are uncommon. While transient hyposmia is frequent, permanent anosmia occurs rarely. Viral-induced anosmia is more common in women and may be associated with a more severe antecedent viral infection [63,64].
Complications of ABRS, which now rarely occur, are related to local extension into the central nervous system (meningitis), orbit of the eye (orbital cellulitis), and periorbital tissues (osteitis of the sinus bones). (See "Preseptal (periorbital) and orbital cellulitis".) Acute sinus infection may also be a precursor of chronic sinus disease, although this relationship is not well studied. (See "Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis".)
INFORMATION FOR PATIENTS — Educational materials on this topic are available for patients. (See "Patient information: Acute sinusitis (sinus infection)".) We encourage you to print or e-mail this topic review, or to refer patients to our public web site, www.uptodate.com/patients, which includes this and other topics.
SUMMARY AND RECOMMENDATIONS
- Acute rhinosinusitis (ARS), inflammation of the nasal cavity and paranasal sinuses lasting less than four weeks, is subdivided into acute viral rhinosinusitis (AVRS) and acute bacterial rhinosinusitis (ABRS). ABRS occurs in 0.5 to 2 percent of episodes. (See 'Introduction' above and 'Pathophysiology' above.)
- The diagnosis of ARS is based on the presence of 1) purulent rhinorrhea and 2) nasal congestion and/or facial pain. Symptoms do not accurately distinguish viral from bacterial infection. ABRS is suggested by the presence of symptoms for seven or more days, especially if symptoms initially improve and then worsen. Cultures from nasal swabs or secretions are inaccurate. Radiography is generally not indicated in the initial evaluation of ARS. (See 'Diagnosis' above.)
- AVRS is expected to resolve within ten days; ABRS may also resolve spontaneously within the first ten days. Patients who present with fewer than 10 days of symptoms, in the absence of high fever or symptoms suggesting complicated illness, should be managed with supportive care. We suggest mild analgesics, systemic or limited-duration topical decongestants, and fluid (Grade 2C). We suggest treatment with intranasal glucocorticoids (Grade 2B). We suggest not treating symptoms with antihistamines or zinc (Grade 2B). (See 'Indications for urgent referral' above and 'Acute viral rhinosinusitis' above.)
- We suggest that patients with mild symptoms lasting more than ten days be treated with observation and supportive therapy (as above) for an additional seven days (Grade 2C). (See 'Observation' above.)
- Nosocomial ABRS is relatively common in patients with prolonged nasotracheal intubation, and often involves gram negative organisms. Nasal foreign bodies should be removed and patients treated with culture-directed antibiotic therapy. Immunosuppressed patients are at risk for acute fulminant invasive fungal rhinosinusitis; treatment involves endoscopic biopsy, emergency surgical debridement, and systemic antifungal therapy. (See 'Nosocomial bacterial rhinosinusitis' above and 'Acute invasive fungal rhinosinusitis' above.)
- Complications of ABRS occur rarely, and include orbital cellulitis, osteitis, and meningitis. (See 'Complications' above.)
